Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A program for relapse prevention in schizophrenia: a controlled study.

M I Herz1, J S Lamberti, J Mintz

  • 1Department of Psychiatry, University of Rochester Medical Center, NY, USA. marvin_herz@urmc.rochester.edu

Archives of General Psychiatry
|March 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamics of Mixed- Candida Species Biofilms in Response to Antifungals.

Journal of dental research·2017
Same author

Multi-state outcome analysis of treatments (MOAT): application of a new approach to evaluate outcomes in longitudinal studies of bipolar disorder.

Molecular psychiatry·2015
Same author

Cirrhosis of the liver; general considerations and a study of 20 cases.

St. Luke's Hospital staff clinics bulletin·2014
Same author

Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression.

Acta psychiatrica Scandinavica·2012
Same author

Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder.

Molecular psychiatry·2012
Same author

Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.

Veterinary and comparative oncology·2012

A relapse prevention program (PRP) significantly reduced relapse and rehospitalization rates in schizophrenia patients compared to treatment as usual (TAU). Early detection of prodromal symptoms improved outcomes.

Area of Science:

  • Psychiatry
  • Clinical Psychology
  • Mental Health Research

Background:

  • Schizophrenia relapse and rehospitalization pose significant challenges for outpatients.
  • Existing treatments, such as treatment as usual (TAU), may not be sufficient for all patients.

Purpose of the Study:

  • To evaluate the effectiveness of a relapse prevention program (PRP) compared to TAU in reducing relapse and rehospitalization rates.
  • To assess the impact of early prodromal symptom detection and intervention on patient outcomes.

Main Methods:

  • Eighty-two outpatients with schizophrenia or schizoaffective disorder were randomized to PRP or TAU for 18 months.
  • PRP included psychoeducation, prodromal symptom monitoring, group therapy, and multifamily groups.
  • TAU involved supportive therapy and medication management.

Related Experiment Videos

Main Results:

  • Relapse rates were 17% in the PRP group versus 34% in the TAU group (P = .01).
  • Rehospitalization rates were 22% in the PRP group versus 39% in the TAU group (P = .03).
  • PRP teams were more effective in identifying prodromal episodes before relapse or hospitalization.

Conclusions:

  • The relapse prevention program (PRP) demonstrated significant efficacy in reducing relapse and rehospitalization.
  • Early identification and intervention for prodromal symptoms, including medication adjustments, are crucial for managing schizophrenia.
  • PRP offers a more effective approach than TAU for long-term management of schizophrenia outpatients.